Determinants of recognition of ligands binding to benzodiazepine receptor/GABAA receptors initiating sedation

被引:12
|
作者
Harris, DL
DeLorey, TM
He, XH
Cook, JM
Loew, GH
机构
[1] Mol Res Inst, Mountain View, CA 94043 USA
[2] Univ Wisconsin, Dept Chem, Milwaukee, WI 53201 USA
关键词
GABA(A)/benzodiazepine receptor; sedation; 3D pharmacophore;
D O I
10.1016/S0014-2999(00)00462-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Complementary behavioral and computational studies of 21 structurally diverse, gamma-amino butyric acid (GABA)(A) benzodiazepine receptor ligands that influence spontaneous locomotor activity have been performed in this work. This behavioral endpoint is a well-accepted indicator of sedation particularly for GABA(A)/benzodiazepine receptor ligands. The goal of the work presented here is the identification and assessment of the minimum requirements for ligand recognition of GABA(A)/benzodiazepine receptors leading to activity at the sedation endpoint embedded in a common 3D pharmacophore for recognition. Using the experimental results, together with a systematic computational procedure developed in our laboratory, a five-component 3D pharmacophore for recognition of the GABA(A) receptor subtypes associated with the sedative behavioral response has been developed consisting of: two proton-accepting moieties, a hydrophobic region, a ring with polar moieties and an aromatic ring in a common geometric arrangement in all ligands having an effect at the sedation endpoint. To provide further evidence that the 3D pharmacophore developed embodied common requirements for receptor recognition, a pharmacophore analysis was performed for agonists, inverse agonists and antagonists separately. Each of the resulting pharmacophores contained the same five moieties at comparable distances to those found for the pharmacophore generated using all of them together. This result confirms that this pharmacophore constitutes a recognition pharmacophore representing required features in the overlapping portion of their binding sites. The reliability of this 3D pharmacophore was then assessed in several ways. First, it was determined that ligands that had no effect at the sedation endpoint did not comply with the pharmacophore requirements. Second, four benzodiazepine receptor ligands known to have an effect at the sedation endpoint, but not used in the pharmacophore development were found to satisfy the requirements of this pharmacophore. Third, the geometric and chemical requirements embedded in this pharmacophore were used to search 3D databases resulting in the identification of benzodiazepine receptor ligands known to affect sedation, but not included in the pharmacophore development. Finally, a SD-quantitative structure analysis procedure (QSAR) model was developed based upon the ligands in the training set superimposed at their sedation pharmacophore points. The 3D-QSAR model shows good predictivity fur binding of these ligands to receptor subtypes containing alpha 1 but not alpha 5 subunits. The pharmacophore developed for the sedation endpoint thus provides a predictive binding model for diverse ligand binding to alpha 1 containing receptor subtypes. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:271 / 287
页数:17
相关论文
共 50 条
  • [31] ALLOSTERIC MODULATION BY BENZODIAZEPINE RECEPTOR LIGANDS OF THE GABAA RECEPTOR CHANNEL EXPRESSED IN XENOPUS OOCYTES
    SIGEL, E
    BAUR, R
    JOURNAL OF NEUROSCIENCE, 1988, 8 (01): : 289 - 295
  • [32] Amino acid residue 200 on the α1 subunit of GABAA receptors affects the interaction with selected benzodiazepine binding site ligands
    Schaerer, MT
    Buhr, A
    Baur, R
    Sigel, E
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 354 (2-3) : 283 - 287
  • [33] A GABAA receptor mutation causing generalized epilepsy reduces benzodiazepine receptor binding
    Fedi, Marco
    Berkovic, Samuel F.
    Marini, Carla
    Mulligan, Rachel
    Tochon-Danguy, Henri
    Reutens, David C.
    NEUROIMAGE, 2006, 32 (03) : 995 - 1000
  • [34] Computational profiling of the binding mechanisms of GABAA receptor ligands
    Kim, Marlene T.
    Lallier, Brian
    Zhang, Jun D.
    Russo, Daniel
    Mayer-Bacon, Chris
    Boison, Abena
    Kotchoni, Simeon O.
    Martin, Joseph V.
    Zhu, Hao
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [35] Structural requirements for ligand interactions at the benzodiazepine recognition site of the GABAA receptor
    Davies, M
    Bateson, AN
    Dunn, SMJ
    JOURNAL OF NEUROCHEMISTRY, 1998, 70 (05) : 2188 - 2194
  • [36] Subunit specificity and binding domains for modulatory ligands in GABAA receptors
    Olsen, RW
    Hanchar, HJ
    Wallner, M
    Chang, CS
    Li, G
    JOURNAL OF NEUROCHEMISTRY, 2005, 94 : 211 - 211
  • [37] Differential contribution of GABAA receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands
    Fradley, Rosa L.
    Guscott, Martin R.
    Bull, Sharlene
    Hallett, David J.
    Goodacre, Simon C.
    Wafford, Keith A.
    Garrett, ELizabeth M.
    Newman, Richard J.
    O'Meara, Gillian F.
    Whiting, Paul J.
    Rosahl, Thomas W.
    Dawson, Gerard R.
    Reynolds, David S.
    Atack, John R.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2007, 21 (04) : 384 - 391
  • [38] A Unified Model of the GABAA Receptor Comprising Agonist and Benzodiazepine Binding Sites
    Bergmann, Rikke
    Kongsbak, Kristine
    Sorensen, Pernille Louise
    Sander, Tommy
    Balle, Thomas
    PLOS ONE, 2013, 8 (01):
  • [39] Conformational changes at benzodiazepine binding sites of GABAA receptors detected with a novel technique
    Berezhnoy, D
    Baur, R
    Gonthier, A
    Foucaud, B
    Goeldner, M
    Sigel, E
    JOURNAL OF NEUROCHEMISTRY, 2005, 92 (04) : 859 - 866
  • [40] ORGN 150-Chemical and pharmacological characterization of new ligands for the benzodiazepine-binding site in the GABAA receptor complex
    Nilsson, Jakob
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234